Mutant DNMT3A in acute myeloid leukemia: Guilty of inducing genetic instability?

Leukemia

Volumn 27, Issue 8, 2013, Pages 1777-1778

  Zebisch, A ^a   Hoefler, G ^a   Quehenberger, F ^a   Wolfler A ^a   Sill, H ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CD135 ANTIGEN; DNA METHYLTRANSFERASE 3A;

ACUTE GRANULOCYTIC LEUKEMIA; EPIGENETICS; GENE DUPLICATION; GENE FREQUENCY; GENE MUTATION; GENOMIC INSTABILITY; HUMAN; INTERNAL TANDEM DUPLICATION; LETTER; LEUKEMIA RELAPSE; PRIORITY JOURNAL;

DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA-BINDING PROTEINS; FMS-LIKE TYROSINE KINASE 3; HUMANS; ISOCITRATE DEHYDROGENASE; LEUKEMIA, MYELOID, ACUTE; MUTATION; PROTO-ONCOGENE PROTEINS;

EID: 84881474171     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.48     Document Type: Letter

References (10)

1. Wakita S, Yamaguchi H, Omori I, Terada K, Ueda T, Manabe E et al. Mutations of the epigenetics-modifying gene (DNMT3a, TET2, IDH1/2) at diagnosis may induce FLT3-ITD at relapse in de novo acute myeloid leukemia. Leukemia 2012, (e-pub ahead of print 8 November 2012). doi:10.1038/leu.2012.317.
2. Fried I, Bodner C, Pichler MM, Lind K, Beham-Schmid C, Quehenberger F et al. Frequency, onset and clinical impact of somatic DNMT3A mutations in therapy-related and secondary acute myeloid leukemia. Haematologica 2012; 97: 246-250.
3. Dicker F, Haferlach C, Sundermann J, Wendland N, Weiss T, Kern W et al. Mutation analysis for RUNX1, MLL-PTD, FLT3-ITD, NPM1 and NRAS in 269 patients with MDS or secondary AML. Leukemia 2010; 24: 1528-1532.
4. Zebisch A, Czernilofsky AP, Keri G, Smigelskaite J, Sill H, Troppmair J. Signaling through RAS-RAF-MEK-ERK: from basics to bedside. Curr Med Chem 2007; 14: 601-623. (Pubitemid 46477731)
5. Zebisch A, Staber PB, Delavar A, Bodner C, Hiden K, Fischereder K et al. Two transforming C-RAF germ-line mutations identified in patients with therapy-related acute myeloid leukemia. Cancer Res 2006; 66: 3401-3408.
6. Fried I, Wolfler A, Quehenberger F, Hoefler G, Sill H, Zebisch A. Mutations inDNMT3A and loss of RKIP are independent events in acute monocytic leukemia. Haematologica 2012; 97: 1936-1937.
7. Kayser S, Dohner K, Krauter J, Kohne CH, Horst HA, Held G et al. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood 2011; 117: 2137-2145.
8. Milosevic JD, Puda A, Malcovati L, Berg T, Hofbauer M, Stukalov A et al. Clinical significance of genetic aberrations in secondary acute myeloid leukemia. Am J Hematol 2012; 87: 1010-1016.
9. Schnittger S, Bacher U, Haferlach C, Alpermann T, Dicker F, Sundermann J et al. Characterization of NPM1-mutated AML with a history of myelodysplastic syndromes or myeloproliferative neoplasms. Leukemia 2011; 25: 615-621.
10. Pichler MM, Bodner C, Fischer C, Deutsch AJ, Hiden K, Beham-Schmid C et al. Evaluation of mutations in the isocitrate dehydrogenase genes in therapy-related and secondary acute myeloid leukaemia identifies a patient with clonal evolution to IDH2 R172K homozygosity due to uniparental disomy. Br J Haematol 152: 669-672.